Loading...
OTCM
NEVPF
Market cap75mUSD
Mar 18, Last price  
0.03
Name

Abliva AB

Chart & Performance

D1W1MN
OTCM:NEVPF chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
67.36%
Rev. gr., 5y
93.89%
Revenues
137k
+341.94%
0908,6604,432,6733,452,7675,556,0001,113,0005,335,0007,152,0002,502,00014,00027,0005,000134,000216,000151,00031,000137,000
Net income
-96m
L+12.41%
-1,227,131-1,557,575-1,528,500-4,773,642-9,386,000-14,873,000-22,331,000-42,549,000-90,119,000-70,240,000-66,728,000-68,373,000-76,874,000-59,883,000-123,498,000-84,964,000-95,509,000
CFO
-103m
L+1,218.12%
-997,923-2,224,735-637,780-5,011,602-8,588,000-12,222,000-19,090,000-43,632,000-67,220,000-57,377,000-58,124,000-63,829,000-72,412,000-67,558,000-114,075,000-159,560,000-7,802,000-102,840,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
URL
https://abliva.com/
IPO date
Oct 03, 2008
Employees
8
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT